SUNNYVALE, Calif., Jan. 5 /PRNewswire/ -- Asthmatx Inc., today announced that it will be presenting at the 28th Annual JPMorgan Healthcare Conference on January 13, 2010, at 3:00 p.m. (PST) at the Westin St. Francis Hotel in San Francisco. During the presentation, Asthmatx will provide an overview of the company and an update on the regulatory status of its Alair® System, a device utilized in Bronchial Thermoplasty for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long acting beta agonists.
About Bronchial Thermoplasty with the Alair System
Bronchial Thermoplasty is a non-drug procedure for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long acting beta agonists. Bronchial Thermoplasty is performed through the working channel of a standard flexible bronchoscope that is introduced through a patient's nose or mouth, and into their lungs. The tip of the small diameter Alair catheter is expanded to contact the walls of targeted airways. Controlled thermal energy is then delivered to the airway walls to reduce the presence of airway smooth muscle that narrows the airways in patients with asthma. The minimally invasive procedure, like many other flexible endoscopy procedures, is done under light anesthesia, and the patient returns home the same day.
Asthmatx is developing catheter-based medical devices for the treatment of asthma. Asthmatx has developed the Alair System to perform an investigational outpatient procedure called Bronchial Thermoplasty. The Alair System has received a CE Mark for use in the European Union, and is under review by the U.S. Food and Drug Administration. For more information on Asthmatx visit www.asthmatx.com.
Alair, Asthmatx and the Asthmatx logo are registered trademarks of Asthmatx, Inc.